Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Grail
MedTech
Grail survives adcomm vote as it awaits FDA decision
Grail has beaten the odds and seen a positive recommendation for its multi-cancer blood test Galleri from FDA advisors.
Ben Adams
Sep 24, 2026 9:10am
Illumina taps new commercial, legal chiefs
Jul 9, 2026 1:26pm
Harbinger raises $100M for new suite of cancer detection tests
Apr 14, 2026 6:00am
BioNTech founders to pioneer new company—Chutes & Ladders
Mar 13, 2026 8:30am
Grail stock craters as Galleri trial fails to hit endpoint
Feb 20, 2026 7:30am
Hims & Hers to sell Grail’s Galleri multi-cancer blood test
Feb 4, 2026 10:55am
